Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic cell vaccine pulsed with tumor cell line or autologous tumor in kidney carcinoma
2006-004751-38Phase 2Completed
- Sponsor
- Oncology Institute of Bari
- Start
- May 2009
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Oncology Institute of Bari. Primary endpoint: Primary. Started May 2009; status: completed.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2006-004751-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004751-38.